AA
TARS icon

AlphaMark Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

AlphaMark Advisors’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-100
Closed -$2K – 714
2022
Q3 		$2K Hold
100
– – ﹤0.01% 611
2022
Q2 		$1K Buy
+100
New +$1.5K ﹤0.01% 607

Other funds holding TARS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AlphaMark Advisors's TARS Position: Q4 2022 in Review

AlphaMark Advisors sold out of Tarsus Pharmaceuticals (TARS) in Q4 2022, closing a stake of 100 shares — an estimated $2K sold.

AlphaMark Advisors first reported a position in TARS in Q2 2022 and held it in 2 quarters. The position peaked at $2K in Q3 2022. 69 funds tracked by Wall St. Rank hold TARS as of Q4 2022.

  • AlphaMark Advisors reported no remaining Tarsus Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • AlphaMark Advisors sold 100 Tarsus Pharmaceuticals shares in Q4 2022, an estimated $2K.
  • AlphaMark Advisors first reported a position in Tarsus Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • AlphaMark Advisors's Tarsus Pharmaceuticals position peaked at $2K in Q3 2022.
  • 69 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q4 2022.

Based on AlphaMark Advisors's 13F filing for Q4 2022, filed 6 Feb 2023.